Enliven Therapeutics Says ELVN-001 Shows Favorable Safety And Tolerability Profile
ReutersMay 14, 2025 3:04 PM
May 14 (Reuters) - Enliven Therapeutics Inc ELVN.O:
ENLIVEN THERAPEUTICS ANNOUNCES UPDATED POSITIVE DATA FROM PHASE 1 CLINICAL TRIAL OF ELVN-001 IN CML AND ORAL PRESENTATION AT THE EHA 2025 CONGRESS
ENLIVEN THERAPEUTICS INC - ELVN-001 SHOWS FAVORABLE SAFETY AND TOLERABILITY PROFILE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Gold trends down for days straight, is the gold bull over?
TradingKey - Gold prices continued to slide in Asia today, falling $196, or more than 5.7%, after down by nearly $72 yesterday, extending the downhill since the 7 May high. By the time this report was published, spot gold was around 3,170 ounces.TradingKey
3 hours ago
Walmart’s Q1 Earnings Could Shift Everything
TradingKey - As Walmart (WMT) approaches its Q1 FY2026 earnings report on May 15th, investor sentiment is optimistic but decidedly laced with apprehension.TradingKey
10 hours ago
Alibaba (BABA) Q4 2024 Earnings Preview: Will the Chinese Tech Rally Continue?
Alibaba will report its fourth quarterly earnings for this fiscal year on Thursday, after the bell. The stock has been performing solidly in the past twelve months with 55% increase, mostly driven by the company’s AI initiatives and recovery in the consumer sentiment in China. Tomorrow we will...TradingKey
Wed, May 14
5 Best Payment Stocks to Buy in 2025
TradingKey - In a world increasingly driven by digital transactions, the payment industry stands as a cornerstone of modern commerce.TradingKey
Thu, Jan 2
US Stock Market’s 2025 Outlook: Navigating the Shifting Landscape
TradingKey - Anyone who has invested in US stocks in 2024 will be happy. The US stock market has delivered an absolutely blockbuster performance so far this year, with the S&P 500 Index soaring 26.9% year-to-date (as of December 16), reaching record highs.TradingKey
Mon, Dec 30
